Skip to main content
. 2015 May 5;6(16):14399–14412. doi: 10.18632/oncotarget.3882

Figure 2. Genes positively regulated by ZEB1 are upregulated in breast cancer bone metastases.

Figure 2

A. Heatmap showing the differential expression of the top 350 ZEB1 target genes, determined from the MDA-MB-231 shCtrl vs. shZEB1 microarray, between bone metastases and other metastatic sites in a set of samples from bone, lung and brain metastases of breast cancer patients (GSE14020). The ER status is depicted with + or −. Genes were ranked according to differential expression in bone metastases vs. other metastatic sites by GENE-E program. 110 out of 350 genes are significantly higher expressed in bone metastases with p < 0.05. The sites of metastases, bone, brain and lung, are indicated in the top row in dark blue, orange and light blue, respectively. B. Gene-Set-Enrichment-Analysis reveals the gene set BONE_METS_UP (adapted from Kang 2003) as enriched in the shCtrl phenotype, which indicates the included genes to be downregulated after stable knockdown of ZEB1 in MDA-MB-231. C. The bone metastatic cell line MDA-BoM-1833 shows highest expression of BMP-inhibitors and ZEB1 when compared to parental MDA-MB-231, lung metastatic MDA-LM2–4175 and luminal breast cancer cell lines T47D and MCF7, analyzed by qRT-PCR and western blot. qRT-PCR data are represented as mean +SD.